Wealth Enhancement Advisory Services LLC Makes New Investment in Twist Bioscience Corporation (NASDAQ:TWST)

Wealth Enhancement Advisory Services LLC acquired a new stake in Twist Bioscience Corporation (NASDAQ:TWST) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,097 shares of the company’s stock, valued at approximately $396,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc increased its stake in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock valued at $27,000 after buying an additional 580 shares during the period. GAMMA Investing LLC increased its stake in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after buying an additional 303 shares during the period. Banque Transatlantique SA acquired a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $43,000. GF Fund Management CO. LTD. acquired a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $58,000. Finally, US Bancorp DE increased its stake in shares of Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after buying an additional 601 shares during the period.

Insider Activity

In related news, insider Dennis Cho sold 689 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $25,940.85. Following the transaction, the insider directly owned 110,849 shares in the company, valued at $4,173,464.85. This trade represents a 0.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Emily M. Leproust sold 5,042 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $189,831.30. Following the completion of the transaction, the chief executive officer owned 655,432 shares in the company, valued at approximately $24,677,014.80. This represents a 0.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 21,911 shares of company stock worth $761,826. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $38.11 on Monday. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -11.73 and a beta of 2.41. Twist Bioscience Corporation has a 52-week low of $27.12 and a 52-week high of $60.90. The stock’s 50 day moving average price is $33.49 and its two-hundred day moving average price is $40.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The business had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. On average, equities analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on TWST. Guggenheim reiterated a “buy” rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their target price on Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Tuesday, May 6th. Barclays reduced their target price on Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group reduced their target price on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Finally, Robert W. Baird reduced their target price on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.